Indian healthcare stocks have delivered exceptional returns, with Nifty Healthcare outperforming NIFTY50 by close to 15% over the last six months, while the broader index lost nearly 2% during the same period. According to latest NSE data, Nifty Healthcare has gained almost 12% on a one-year basis compared to NIFTY50's loss of around 8%. This sustained outperformance reflects growing investor confidence in healthcare sectors with visible earnings potential amid geopolitical crisis impacts on broader markets. As per Red Lions Capital's Saikat Kumar, investors are gravitating toward sectors with relatively visible earnings like healthcare, driven by defensive characteristics, resilient earnings, and improving fundamentals across hospitals, diagnostics, and select pharma segments.
According to the latest Fund Folio: Indian Mutual Fund Tracker report by Motilal Oswal Financial Services, mutual funds made significant sector allocation changes in August 2026. Healthcare allocation increased from 8.1% in July to 8.4% in August, marking the fourth consecutive monthly increase and taking the sector's weight to a 71-month high. This sustained upward trend reflects growing investor confidence in the healthcare sector. Additionally, capital goods allocation also saw an increase, indicating mutual funds' strategic shift toward infrastructure and industrial sectors.
Several healthcare stocks have emerged as standout performers in recent months. Laurus Labs leads with a remarkable 100.8% return over six months and 78% year-to-date, followed by Divi's Lab at 52.7% six-month return and 47.7% year-to-date. Zydus Lifesciences has delivered 28.6% six-month returns and 26.4% year-to-date, while Apollo Hospitals recorded 18.2% six-month gains and 24.2% year-to-date. Aurobindo Pharma has gained 33.9% over six months and 43% year-to-date, demonstrating the sector's broad-based strength across pharmaceuticals and hospital chains.
According to the latest Fund Folio: Indian Mutual Fund Tracker report by Motilal Oswal Financial Services, mutual funds were net buyers in 42% of Nifty 50 stocks in August 2026, covering 21 large-cap stocks. Among the top gainers, Dr Reddy's Laboratories saw the highest increase with shares rising 11.4% from July 2026, with mutual funds holding 11.86 crore shares as of August 2026. Coal India followed with a 9.9% increase, while Tata Steel and Max Healthcare Institute recorded increases of 4.3% and 4.2% respectively. On the selling side, Grasim Industries recorded the sharpest decline with shares falling 9.7% month-on-month.
Despite current challenges including regulatory concerns and US generics pricing pressure, market experts remain optimistic about the healthcare sector's long-term prospects. Bernstein Research predicts that India's healthcare sector could grow to $195 billion over the next decade, with rainmakers in 505(B)(2) NDAs, orphan indications, and cellular therapies like CAR-T potentially adding $70-75 billion to industry size. Key growth drivers include increasing patient volumes, premiumisation of healthcare services, capacity expansion, and rising healthcare penetration. Nomura analysts expect AI and automation adoption to create around $400 billion in opportunities for the sector, while Bernstein highlights that the market is pricing in domestic growth but not emerging markets expansion.
